Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease <i>via</i> the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study

<div>Schematic representation summarizing the role of dehydrovomifoliol in NAFLD. Dehydrovomifoliol downregulates E2F1 to inactivate the AKT/mTOR signaling pathway, thereby improving fat metabolic abnormalities and alleviating NAFLD.</div>

Evidence-Based Complementary and Alternative Medicine

fig8

Figure 8

Figure 8: Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease <i>via</i> the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study 

Figure 8 | Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study 